What’s ahead for Diabetes Medtech in 2025 and beyond?

A round up of developments that could change diabetes management this year.We’re looking at the key players in the diabetes medtech sector.

Peer into our crystal ball to gain an understanding of near future developments with CGM technology.

It's pretty clear that medtech initially intended for diabetes management is no longer the preserve of those with the condition.

Abbott and Dexcom have both moved into the wellness and nutrition market with the Lingo and Stelo respectively and they also provide sensors to others in this sector, such as Zoe whose package includes a Libre sensor and Levels that offers a choice of a Libre 2 or Dexcom G6 sensor.

And now they are setting their sights on targeting type 2s not using insulin, which accounts for a global market estimated at being worth USD $79 billion by 2034. This reflects the increasing prevalence of the condition, advancements in technology, and ongoing research and development.

The potential rewards in this sector are huge, worth so much more than diabetes medtech.  

Non-invasive glucose monitoring has been the goal for many tech compnaienis, not just those involved in diabetes with Google and Apple interested in developing into this area.

2025 is likely to see advancements in this area, especially as far as health and fitness is concerned. Accuracy has always been the issue, but without the need for medical regulatory clearance this could be the direction glucose monitoring is heading. 

With Dexcom's investment in Öura, could rings be the future of glucose monitoring?

What about the use of AI? Dexcom have already integrated this into their Stelo app, marketed to type 2s and those using a CGM for health and wellness, to provide personalised insights.

The future is likely to be less focus on type 1 management but greater interoperability, more personalised insights with the use of AI and more wearable options such as integration with rings or perhaps other jewellery....

Read on to see what's on the horizon.  

Abbott (FreeStyle Libre)

Could a CKM spell the end for ketone urine tests?

Continuous ketone monitors

It’s been a few years since first announced, but a new device capable of measuring both blood sugar and ketones is on the verge of becoming a reality with Abbott’s continuous ketone monitor (CKM). The device is expected to mirror, or be similar to, the form of a FreeStyle Libre 3 sensor and will provide real-time alerts for rising ketone levels, helping to prevent diabetic ketoacidosis (DKA).

According to Abbott, there is a pressing need for a continuous glucose-ketone monitor for individuals who are at higher risk of developing ketoacidosis and this will be the first-of-its-kind for dual monitoring.

Currently, monitoring of ketones is intermittent and often only done when suffering from illness, an infection is suspected or symptoms of DKA become evident. With continuous monitoring, rising ketone levels could be detected early.

A CKM could also enable those with type 1 diabetes to safely use SGLT inhibitors—medications - potentially opening the door for FDA approval of these treatments for type 1 diabetes.

Abbott are known to have been developing this medtech since at least 2022, with trials in 2023 and they already have breakthrough approval for the device from the FDA in the US.

Dexcom have also stated that they are working on new sensor probes that could involve measuring ketones in addition to insulin. 

So, could this spell the end for ketone urine tests in 2025?

FreeStyle Libre 2 discontinuation

It was announced towards the end of last year that the FreeStyle Libre 2 is being discontinued in the UK and users would need to move to the FreeStyle Libre 2 Plus CGM by August 2025. See this news here. 

Libre 2 Plus is generally available in the UK on the NHS for individuals managing type 1 diabetes not using a pump. The Libre 3 is typically prescribed to those using a hybrid closed loop. Note, this may differ across the UK and may be based on individual factors.

Lingo biosensor

The Lingo - a CGM aimed at individuals interested in wellness and nutrition - is expected to be launched widely across the US and it looks to be big!

Lingo is already available in the UK and the advertising so far has been very strong, particularly on social media. It seems to target a similar market to those using Zoe, which also uses a Libre sensor. 

Biosensor is the term used by some medtech companies to differentiate products aimed at individuals who do not have diabetes. Terminology also refers to bio wearables for glucose tracking, rather than continuous glucose monitors.

Rio biosensor

Image credit: Abbott

The Rio is also expected to become available in 2025 but no specific details have been released by Abbott yet including where it will be launched or pricing. 

Rio will be Abbott’s first over-the-counter CGM in the US ie. it can be bought without a prescription. It will be aimed at adults aged 18 and older with Type 2 diabetes who do not use insulin and who primarily manage their condition through lifestyle changes.

Rio is expected to be the first non-prescription CGM with a measurement range of 40 mg/dL to 400 mg/dL, allowing for the measurement of extremely high or extremely low glucose levels, according to Abbott.

Rio is likely to be a direct competitor to Dexcom's Stelo using a Libre 2 sensor with a separate app for smartphones or a reader. The app is likely to provide users with suggested lifestyle modifications to lower glucose levels, such as nutrition and exercise guidance. 

Although FreeStyle Libre CGMs have been available without a prescription in over 50 countries for the past decade, they have only been accessible by prescription in the US until now.

In summary, Abbott's product range currently look like this:

FreeStyle Libre - aimed at type 1 diabetes management those using insulin. Lingo - for individuals who don't have diabetes. For glucose tracking in relation to nutrition and wellness. Rio - aimed at type 2 management, those not using insulin.

Abbott & Medtronic (as partners)

In August 2024, Medtronic and Abbott announced they have joined forces to develop an integrated CGM. Under the partnership, Abbott will provide Medtronic with a CGM designed to work exclusively with Medtronic's smart dosing devices and software, including both automated insulin delivery (AID)/hybrid closed loop systems and Smart MDI setups.

This collaboration could be a game-changer, addressing one of the main reasons many people avoided Medtronic pumps in the past—the design and form factor of their sensors ie. Guardian Connect. Development of the new system, based on the FreeStyle Libre 3 sensor, is already underway.

Dexcom

Image credit: Dexcom Inc.

Dexcom G8

The next Dexcom CGM is already at the trial stage with a limited number of individuals understood to be wearing these for testing. No precise details of function or form yet - but Dexcom's CEO recently stated that "it will be smaller, less expensive and include better electronics". We're sure we will learn more about this during 2025.

Dexcom G7 - 15 day sensor

Dexcom has already submitted an application to the FDA for a 15-day sensor for the G7 CGM and it’s hoped approval will come in 2025. Currently, the G7 offers a wear time of 10.5 days, so this upgrade would extend monitoring by an additional 5 days and reduce the number of sensors needed each month from three to just two.

Approval is anticipated based on the fact that Dexcom's over-the-counter CGM, Stelo - for people with type 2 diabetes not using insulin—has already been approved as a 15-day sensor.

Of course, the G7 competes with Abbott’s FreeStyle Libre products with the Libre 2 Plus and 3 Plus already having a 15-day wear period.

Dexcom G6

In the US, Dexcom have announced that the G6 is being discontinued and this has also recently been confirmed in Australia.

Whilst there's no news of the G6 disappearing in the UK yet, it's likely to be 'on the cards' with the Dexcom ONE no longer listed online, and there's recently been a big marketing promotion pushing the ONE+ CGM - a G7 sensor with more limited functionality.  

Dexcom state that "G6 users on AID systems will continue to have access to Dexcom G6 until Dexcom G7 pump integrations become fully available".

Information from Dexcom about the discontinuation of G6 in the US is available here.

Dexcom Stelo

Dexcom's CEO recently reported that by the end of 2024 there were around 140,000 users of Stelo - their glucose sensor and app aimed at type 2s who don't use insulin. Most users took out a subscription and purchasers also included those interested in tracking glucose for health and wellness as well as pre-diabetes.

We expect use of Stelo to grow significantly in 2025 with more coverage in the US. It will be available from Amazon as well as directly being sold by pharmacies.

Dexcom & Oura ring partnership

Image credit: Öura

Following the announcement in 2024 that Dexcom and Oura plan to integrate CGM datawith health and fitness data, it's anticipated that this functionality will become available in the first half of 2025.

Readings will appear in the Oura and Dexcom apps to shed light on how sleep, stress, vital signs, and other factors affect blood sugar levels. Oura rings sell for between £349 and £499 ($299 - $449), depending on the style.

Dexcom are also planning for more integrations in 2025, with meal-tracking apps such as My FitnessPal. 

Eversense

Image credit: Eversense 365

The Eversense 365 implantable CGM can be worn for up to 365 days and received approval in 2024 with an iCGM designation. This makes it possible to integrate with a pump and become part of  a hybrid closed loop / automated insulin delivery (AID) system.

It’s known that Eversense are already in discussions with several pump manufacturers, and a partnership announcement is anticipated in 2025.

Medtronic

Image credit: Medtronic

In Europe, Medtronic's MiniMed 780G System with Simplera Sync, all-in-one sensor was approved and launched in 2020. It is now Europe's most utilised automated insulin delivery (AID) system.

The Simplera system has only recently been rolled out in the UK and whilst the Simplera received FDA approval in July 2024, Simplera Sync has yet to receive approval by the FDA for use in the US.

Omnipod

Omnipod, part of Insulet Corporation, announced in January 2025 that the Omnipod 5 is now available in five more countries—Italy, Denmark, Finland, Norway, and Sweden. This follows successful launches in the UK, Germany, Netherlands, and France.

In 2024 Omnipod was named the number 1 insulin pump chosen by new pump users in Europe.

The tubeless patch pump can pair with CGMs including Dexcom G6 and FreeStyle Libre 2 Plus, to automatically adjust insulin delivery. Omnipod 5 is the first and only tubeless automated insulin delivery (AID) system integrated with both leading CGM sensor brands.

In the second half of 2024, Omnipod 5 was cleared by the FDA for type 2 diabetes management in the US.

Twiist

Image credit:  Sequel Med Tech

The twiist (a product of Sequel) received FDA approval in 2024 and is expected to be available by June 2025, though it's not known if this will be just in the US.

It will be the first AID/hybrid closed loop system capable of directly measuring insulin delivery volume and flow, allowing for rapid detection of obstructions or occlusions. It operates using the Tidepool Loop algorithm and is designed to be compatible with various iCGMs.

Twiist differs from other insulin pumps because it has no syringes, no gears and no motors, unlike most current pumps that use a tiny motor that rotates, causing a plunger to push insulin into the tubing. Weighing under 2 ounces, the pump is water-resistant and holds 300 units of insulin with the ability to measure the amount of insulin actually delivered.

One of the founders of Sequel, Dean Kamen, is credited with inventing the first portable insulin pump in the ’70s, by the National Inventors Hall of Fame. He is also the inventor of the Segway!

Tidepool

Image credit:Tidepool Project

Integration with FreeStyle Libre

Tidepool - a nonprofit company providing diabetes-related software - recently announced plans to integrate data from FreeStyle Libre CGMs into Tidepool+, its online platform for viewing data from various diabetes devices.

Beta Bionics

Image credit:Beta Bionics

New patch pump

Beta Bionics, a developer of diabetes technology, is working on a tubeless patch pump set for release in 2027 as part of its iLet Bionic Pancreas automated delivery system.

The company explained that the device consists of two components. The first is a reusable unit containing the electronics and motor that power the device. The second is a disposable piece that includes an adhesive patch, insulin reservoir, insertion device, and cannula for insulin delivery.

Patch pumps are designed to stick directly to the skin using an adhesive. Currently, the Omnipod is the only tubeless patch pump available for people with type 1 and type 2 diabetes. Smaller pumps, such as the Tandem Mobi and the upcoming twiist pump, use a thin tube and cannula to deliver insulin. These smaller devices can be inserted into a sleeve with adhesive backing, making them resemble patch pumps.

Beta Bionics plans to initially market the pump to individuals with type 1 diabetes, with plans to expand its use to those with type 2 diabetes. The company also mentioned that it is developing an AID system that not only uses insulin to lower blood sugar but also includes glucagon to raise blood sugar. While research into dual-hormone systems is ongoing, none are currently available for people with diabetes.

Read about the integration of iLet with FreeStyle Libre 3 Plus here.

Investment

Beta Bionics recently announced that were looking for raise funds for development of its iLet automated insulin delivery system (AID) which will be a bihormonal device- enabling the automatic delivery of insulin and glucagon to raise glucose levels and prevent hypos. 

Beta Bionics aim is to launch the new patch pump by the end of 2027.

At the end of September 2024, Beta Bionics had 11,214 customers using its tubed insulin pump.

Tandem

Image credit: Tandem

Tandem's integration with FreeStyle Libre 3 Plus (already announced in July 2024) is planned for 2025 and the rollout will begin with the t:slim X2 pump, in the US and internationally,followed by the Tandem Mobi pump.

"Tobi"

Tandem’s Tubeless Mobi, informally known as "Tobi," is essentially the same pump as the original Mobi but with a redesigned cartridge that eliminates the need for tubing, allowing for direct insulin delivery. The key innovation here is flexibility—users can switch between tubed and tubeless configurations with each cartridge change, tailoring their pump setup to their needs. 

This could be Tandem’s first entry into the tubeless pump market and may be one to watch for 2025.

Ypsomed

Image credit: Ypsomed

Ypsomed, a Swiss market leader in diabetes care, whose pump integrates with mylife Diabetes care and CamAPS FX announced in January 2025 that following a growth in sales in the 2024/25 financial year, it was looking to initiate the sale of Diabetes Care.

Ypsomed markets its products under the umbrella brand mylife Diabetescare and  partners with many pharmaceutical and biotech companies for pens, autoinjectors and pump systems.

The company reports show that the mylife Loop solution for automated insulin delivery has around 60,000 active users (as at end of September 2024). Users are primarily based in Germany, France, the United Kingdom, Australia and Spain.  

Other medtech developments

It may look like a busy year ahead already in the world of medtech, but there are still plenty of other possible innovations - new CGMs, new partnerships, integrations, apps, smartPens, use of AI and more in terms of wearables.

We can probably expect to hear from Roche regarding their Accu-Check CGM as this was expected in the second half of 2024. And, there's also the Syai Tag CGM from Singapore - it's slightly smaller than a Libre 3 - and MODD1 patch pump to keep an eye out for. Modular Medical are known to be preparing to submit data for CE approval of the MODD1 in Europe, this year.

In China there are over 12 CGM providers to choose from and many of these are probably looking to expand to the UK, Europe, US and beyond.

If we include medtech providers with plans to offer non-invasive glucose monitoring, there are many more businesses with a focus on glucose tracking and measurement. It's interesting to hear of the innovative approaches being taken.

For example, there are companies working on providing glucose data from scanning your hand or wrist with a laser, others looking at how to record glucose levels based on EEG data from tech worn behind the ear and another developing a measurement tool from a persons breath.

One stand-out company to watch is Moglu, who are developing Raman spectroscopy technology, to detect glucose-reactive signals on the skin. They are aiming for FDA approval in 2025 and believe that MOGLU could potentially become the first FDA-approved noninvasive CGM.

On the one hand, it's great to know there's lots of interest in medtech here, but it's not all for the benefit of diabetes management. Let's consider if there's anything else that  could impact diabetes management in 2025?

Big Pharma have been working on once-weekly basal insulin for a number of years, however, despite Eli Lilly and Novo Nordisk presenting insulin capable of this, for regulatory approval, the insulins did not receive the clearance needed. It's likely that new formulations will be developed and presented in 2025.

There's lots to be excited about! And if I end this article with one prediction, it's that  2025 will be the year that we see glucose data collected directly by watches and integration with rings too. 

Love My Libre set out to transform medtech to be like jewellery and now it seems the medtech world are seeing this too!

___________________

Thank you for reading. 

---